ADReCS

Pharmaceutical Information

Drug Name	Piroxicam
Drug ID	BADD_D01784
Description	A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily.
Indications and Usage	For treatment of osteoarthritis and rheumatoid arthritis.
Marketing Status	approved; investigational
ATC Code	M01AC01; M02AA07; S01BC06
DrugBank ID	DB00554
KEGG ID	D00127
MeSH ID	D010894
PubChem ID	54676228
TTD Drug ID	D00IBN
NDC Product Code	72789-211; 0093-0757; 71335-1999; 51927-1699; 70771-1429; 71335-2067; 72189-350; 22365-114; 59348-0014; 0093-0756; 29033-012; 42543-114; 71335-9622; 17337-0538; 38779-0302; 46438-0053; 49452-5476; 29300-255; 63629-9149; 0069-3220; 42291-674; 55700-697; 0069-3230; 62991-1113; 42291-677; 42571-177; 63629-9148; 71205-032; 72789-210; 59762-0145; 63629-9150; 53747-044; 60715-3270; 59762-0140; 64380-843; 70771-1430; 51927-0145; 60592-604; 63187-972; 64380-842; 71205-203; 46438-0639; 68981-041; 29033-013; 29300-256; 42543-115; 42571-176
UNII	13T4O6VMAM
Synonyms	Piroxicam \| CP-16171 \| CP 16171 \| CP16171 \| Feldene

Chemical Information

Molecular Formula	C15H13N3O4S
CAS Registry Number	36322-90-4
SMILES	CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Somnolence	19.02.05.003; 17.02.04.006	-	-
Stevens-Johnson syndrome	10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.005	-	-
Stomatitis	07.05.06.005	-	-
Swelling	08.01.03.015	0.010104%		Not Available
Syncope	02.11.04.015; 17.02.04.008; 24.06.02.012	-	-
Tachycardia	02.03.02.007	-	-	Not Available
Tension	19.06.02.005	-	-	Not Available
Thirst	14.03.02.007; 08.01.09.021	-	-	Not Available
Thrombocytopenia	01.08.01.002	0.001064%		Not Available
Tinnitus	17.04.07.004; 04.04.01.002	0.002340%
Toxic epidermal necrolysis	10.01.01.006; 23.03.01.008; 12.03.01.015; 11.07.01.006	0.001064%
Tremor	17.01.06.002	-	-
Tricuspid valve incompetence	02.07.05.001	0.001064%		Not Available
Ulcer	08.03.06.001	-	-	Not Available
Urinary retention	20.02.02.011	0.001595%
Urticaria	23.04.02.001; 10.01.06.001	0.023293%
Vascular purpura	24.07.06.011; 23.06.01.008; 01.01.04.007	-	-	Not Available
Vasculitis	24.12.04.027; 10.02.02.006	-	-
Vertigo	17.02.12.002; 04.04.01.003	-	-
Vision blurred	17.17.01.010; 06.02.06.007	-	-
Visual impairment	06.02.10.013	0.001064%		Not Available
Vomiting	07.01.07.003	-	-
Weight increased	13.15.01.006	-	-
Tubulointerstitial nephritis	20.05.02.002	0.002127%		Not Available
Acute generalised exanthematous pustulosis	11.07.01.018; 10.01.01.034; 23.03.10.002; 12.03.01.005	0.005850%		Not Available
Hypoacusis	04.02.01.006	-	-
Peripheral swelling	08.01.03.053; 02.05.04.015	0.002872%		Not Available
Contusion	15.03.05.007; 24.07.06.001; 23.03.11.002; 12.01.06.001	-	-
Acute coronary syndrome	24.04.04.011; 02.02.02.015	-	-	Not Available
Musculoskeletal stiffness	15.03.05.027	-	-	Not Available

The 7th Page First Pre 7 8 9 Next Last Total 9 Pages